Zacks Investment Research upgraded shares of Ekso Bionics (NASDAQ:EKSO) from a hold rating to a buy rating in a report issued on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $0.75 price objective on the stock.
According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “
Several other equities analysts have also weighed in on the stock. ValuEngine lowered shares of Ekso Bionics from a hold rating to a sell rating in a report on Friday, November 1st. Cantor Fitzgerald assumed coverage on shares of Ekso Bionics in a report on Friday, September 6th. They set an overweight rating and a $1.00 target price for the company. HC Wainwright assumed coverage on shares of Ekso Bionics in a report on Monday, October 28th. They set a buy rating and a $1.20 target price for the company. Finally, Aegis reaffirmed a buy rating and set a $2.90 target price on shares of Ekso Bionics in a report on Thursday, August 8th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Ekso Bionics has an average rating of Buy and an average price target of $1.46.
Shares of NASDAQ:EKSO traded down $0.01 during trading on Wednesday, reaching $0.60. The stock had a trading volume of 542,300 shares, compared to its average volume of 446,929. The company has a current ratio of 2.11, a quick ratio of 1.69 and a debt-to-equity ratio of 0.28. Ekso Bionics has a one year low of $0.48 and a one year high of $2.55. The firm’s 50-day simple moving average is $0.57 and its 200 day simple moving average is $1.09. The company has a market capitalization of $47.22 million, a P/E ratio of -1.36 and a beta of 1.60.
Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings data on Wednesday, October 30th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. Ekso Bionics had a negative net margin of 100.36% and a negative return on equity of 376.63%. The business had revenue of $3.32 million during the quarter. Equities research analysts forecast that Ekso Bionics will post -0.3 earnings per share for the current fiscal year.
Large investors have recently bought and sold shares of the company. Wells Fargo & Company MN increased its holdings in shares of Ekso Bionics by 4,401.9% during the 2nd quarter. Wells Fargo & Company MN now owns 49,521 shares of the company’s stock valued at $63,000 after purchasing an additional 48,421 shares in the last quarter. CVI Holdings LLC purchased a new position in shares of Ekso Bionics during the 2nd quarter valued at approximately $494,000. BlackRock Inc. increased its holdings in shares of Ekso Bionics by 123.2% during the 2nd quarter. BlackRock Inc. now owns 813,996 shares of the company’s stock valued at $1,035,000 after purchasing an additional 449,348 shares in the last quarter. Wasatch Advisors Inc. purchased a new position in shares of Ekso Bionics during the 2nd quarter valued at approximately $2,398,000. Finally, Vanguard Group Inc. increased its holdings in shares of Ekso Bionics by 41.2% during the 2nd quarter. Vanguard Group Inc. now owns 2,085,186 shares of the company’s stock valued at $2,648,000 after purchasing an additional 608,759 shares in the last quarter. 36.44% of the stock is owned by hedge funds and other institutional investors.
Ekso Bionics Company Profile
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through EksoHealth and EksoWorks segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries and hemiplegia due to stroke.
Featured Story: Penny Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.